EA201000076A1 - Новые конструкты для экспрессии вируса гриппа - Google Patents

Новые конструкты для экспрессии вируса гриппа

Info

Publication number
EA201000076A1
EA201000076A1 EA201000076A EA201000076A EA201000076A1 EA 201000076 A1 EA201000076 A1 EA 201000076A1 EA 201000076 A EA201000076 A EA 201000076A EA 201000076 A EA201000076 A EA 201000076A EA 201000076 A1 EA201000076 A1 EA 201000076A1
Authority
EA
Eurasian Patent Office
Prior art keywords
expression
rna
promoter
flu virus
new structures
Prior art date
Application number
EA201000076A
Other languages
English (en)
Other versions
EA017456B1 (ru
Inventor
Маркус Волшек
Андрей Егоров
Михаэль Бергманн
Томас Мустер
Христиан Киттель
Original Assignee
Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг filed Critical Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг
Publication of EA201000076A1 publication Critical patent/EA201000076A1/ru
Publication of EA017456B1 publication Critical patent/EA017456B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение представляет линейный экспрессирующий конструкт, не содержащий никаких последовательностей для амплификации и/или селекции, который содержит промотор РНК-полимеразы I (polI) и сигнал терминации polI, вставленные между промотором РНК-полимеразы II (polII) и сигналом полиаденилирования, пригодный для экспрессии сегментов вирусной РНК, предпочтительно РНК вирусов гриппа. Патентоспособный конструкт полезен для эффективного и быстрого получения вирусных частиц, особенно для получения рецептур вакцин для лечения эпидемических и/или пандемических заболеваний.
EA201000076A 2007-06-27 2008-06-26 Новые конструкты для экспрессии вируса гриппа EA017456B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94665107P 2007-06-27 2007-06-27
EP07450177A EP2045323A1 (en) 2007-10-05 2007-10-05 Linear expression constructs for production of influenza virus particles
PCT/EP2008/058182 WO2009000891A2 (en) 2007-06-27 2008-06-26 Linear expression constructs for production of influenza virus particles

Publications (2)

Publication Number Publication Date
EA201000076A1 true EA201000076A1 (ru) 2010-06-30
EA017456B1 EA017456B1 (ru) 2012-12-28

Family

ID=39099653

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000076A EA017456B1 (ru) 2007-06-27 2008-06-26 Новые конструкты для экспрессии вируса гриппа

Country Status (9)

Country Link
US (1) US20100129399A1 (ru)
EP (2) EP2045323A1 (ru)
CN (1) CN101952427A (ru)
AU (1) AU2008267180B2 (ru)
CA (1) CA2689569C (ru)
EA (1) EA017456B1 (ru)
IN (1) IN2009KN04355A (ru)
NZ (1) NZ582102A (ru)
WO (1) WO2009000891A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9091510B2 (en) 2007-03-21 2015-07-28 Schott Corporation Transparent armor system and method of manufacture
EP2072058A1 (en) 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
EP2233568A1 (en) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
CN102597246B (zh) 2009-05-21 2014-02-26 诺华股份有限公司 使用非内源pol I启动子的反向遗传
EP2459722B1 (en) * 2009-07-31 2017-09-06 Seqirus UK Limited Reverse genetics systems
CA2778332A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
JP2013529913A (ja) * 2010-06-02 2013-07-25 アヴィール グリーン ヒルズ バイオテクノロジー リサーチ ディベロプメント トレード アクチエンゲゼルシャフト Ｒｎａウィルスの作製のための方法及びヘルパーウィルス
CN102495208B (zh) * 2011-10-24 2014-03-26 山东省农业科学院畜牧兽医研究所 禽流感病毒rt-pcr elisa试剂盒
US10206997B2 (en) * 2011-11-10 2019-02-19 Bin Wang Facilitator-DNA combination vaccine
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
WO2014086732A2 (en) 2012-12-03 2014-06-12 Novartis Ag Influenza virus reassortment
MX2015011529A (es) 2013-03-13 2016-02-05 Novartis Ag Reordenamiento del virus de infuenza b.
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
WO2014195920A2 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
EP3764098B1 (en) 2015-07-07 2022-11-16 Seqirus UK Limited Influenza potency assays
JP2023502650A (ja) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド 遺伝子再集合インフルエンザウイルスを産生するための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400445T3 (es) * 1998-06-12 2013-04-09 Mount Sinai School Of Medicine Virus atenuados con cadena de polaridad negativa con actividad antagonista de interferón alterada para uso como vacunas y productos farmacéuticos
CA2334857C (en) * 1998-06-12 2012-03-20 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
AU4032300A (en) * 1999-03-24 2000-10-09 Gene Therapy Systems, Inc. Method for generating transcriptionally active dna fragments
DK1185615T3 (da) * 1999-04-06 2007-11-05 Wisconsin Alumni Res Found Rekombinante influenzavirus til vacciner og genterapi
ATE353370T1 (de) * 1999-07-14 2007-02-15 Sinai School Medicine In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
SI1317559T1 (sl) * 2000-04-28 2009-04-30 St Jude Childrens Res Hospital Sistem transfekcije dna za pripravo infektivne negativne verige virusne rna
DK1499348T3 (en) * 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
ATE469972T1 (de) * 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
WO2006083286A2 (en) * 2004-06-01 2006-08-10 Mount Sinai School Of Medicine Of New York University Genetically engineered swine influenza virus and uses thereof
US7968101B2 (en) * 2004-11-19 2011-06-28 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
US8043856B2 (en) * 2007-06-14 2011-10-25 Wisconsin Alumni Research Foundation Adenoviral vectors for influenza virus production

Also Published As

Publication number Publication date
WO2009000891A3 (en) 2009-02-26
CA2689569A1 (en) 2008-12-31
EP2160462B1 (en) 2017-07-26
CN101952427A (zh) 2011-01-19
EA017456B1 (ru) 2012-12-28
US20100129399A1 (en) 2010-05-27
EP2045323A1 (en) 2009-04-08
AU2008267180A1 (en) 2008-12-31
WO2009000891A2 (en) 2008-12-31
AU2008267180B2 (en) 2014-07-10
EP2160462A2 (en) 2010-03-10
CA2689569C (en) 2020-10-27
IN2009KN04355A (ru) 2015-07-10
NZ582102A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
EA201000076A1 (ru) Новые конструкты для экспрессии вируса гриппа
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
GT201300093A (es) Compuestos antivirales
TW200732476A (en) Functional influenza virus like particles (VLPs)
EA200970013A1 (ru) Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
UY34983A (es) Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas
EA201590384A1 (ru) 6-аминокислота-гетероарилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
EA201001045A1 (ru) Модифицированный вирус гриппа
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
WO2009143524A3 (en) Nanoemulsion vaccines
DK1951296T3 (da) Celleafledte virale vacciner med lave niveauer af restcelle-DNA
EA201290897A1 (ru) Вакцины для пандемического гриппа
EP2078083A4 (en) NEW DOG INFLUENZA VIRUS AND VEGETABLE THEREFOR
EA202190602A2 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
EA201390806A1 (ru) Конструкция пептидного каркаса
CL2008003819A1 (es) Compuestos derivados del acido 2-cetoamino benzoico sustituido, inhibidores del virus de la hepatitis c; composicion farmaceutica; y su uso en el tratamiento de una infeccion por vhc.
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
EA201171370A1 (ru) Универсальные способы определения вирусов гриппа
BR112017006680A2 (pt) variantes de vírus influenza a
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
ATE508185T1 (de) Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU